PTPN1 and metabolic dysfunction-associated steatotic liver disease: Integrating previous research findings, it is evident that PTP1B shows promise as a critical target for acute liver injury, non-alcoholic fatty liver disease (NAFLD), and hepatocellular carcinoma (HCC).